New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 28, 2013
09:26 EDTDNDN, GTIV, ABFS, ACI, ACN, LHCG, AMED, SNY, MCP, BBRY, AFAM, PFE, BIIBOn The Fly: Pre-market Movers
HIGHER: Dendreon (DNDN), up 9.8% after getting positive EU opinion for Provenge drug... Arkansas Best (ABFS), up 10% after ABF Freight System employees represented by Teamsters ratify five-year national labor agreement... Molycorp (MCP), up 7.8% after SEC completes investigation with no enforcement action recommended... Arch Coal (ACI), up 8.9% after announcing will sell non-core Utah operations to Bowie Resources for $435M... Biogen (BIIB), up 5.8% after the European Medicines Agency granted Sanofi's multiple sclerosis drug Aubagio "new active substance" status. Sanofi, which also received a positive CHMP opinion for Lemtrada, up 1.5%... Pfizer (PFE), up 1% after boosting share buyback program by $10B. DOWN AFTER EARNINGS: BlackBerry (BBRY), down 23%... Accenture (ACN), down 9%... Nike (NKE), down 0.8%. ALSO LOWER: Home health agencies, including Amedisys (AMED), down 21%, Gentiva Health (GTIV), down 16%, Almost Family (AFAM), down 13%, and LHC Group (LHCG), down 12%, after the Centers for Medicare & Medicaid Services proposed 2014 reimbursement cuts.
News For BBRY;ACN;DNDN;MCP;ACI;BIIB;SNY;ABFS;PFE;AMED;GTIV;AFAM;LHCG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 15, 2014
08:02 EDTPFEPfizer, OPKO Health enter into global agreement for hGH-CTP
Subscribe for More Information
07:36 EDTBBRYBlackBerry December volatility elevated into Q3 and outlook
Subscribe for More Information
December 12, 2014
09:08 EDTACNHatch to look to push tech worker bill, Reuters reports
Subscribe for More Information
08:01 EDTBIIBPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
13:19 EDTBBRYMicrosoft dropped by Ford for in-car sync system, Re/code reports
Ford's (F) Sync 3 in-car entertainment and mapping system will use a version of BlackBerry's (BBRY) QNX operating system, replacing Microsoft (MSFT) technology that had been used in the prior two versions, Re/code reports. The QNX-powered system adds more features, including a capacitive touch screen and the ability to get software updates over Wi-Fi. Ford said in a statement that its "hardware and software decisions were based on identifying the technology that would best meet the expectations for performance by our customers." Reference Link
09:59 EDTBBRYBlackBerry December volatility increases into Q3 and outlook
Subscribe for More Information
December 10, 2014
08:52 EDTACNAccenture December volatility elevated into Q1 and outlook
Subscribe for More Information
08:31 EDTPFETeva announces launch of first generic Celebrex capsules in the U.S.
Teva Pharmaceutical Industries (TEVA) announces the launch of the first FDA-approved generic equivalent to Celebrex Capsules in the United States. Teva is offering 50, 100, 200, and 400 mg strengths of Celecoxib Capsules. Celebrex Capsules, marketed by Pfizer (PFE) had annual sales of approximately $2.56B in the United States, according to IMS data as of October 2014.
07:38 EDTPFEMylan launches generic version of Pfizer's Celebrex capsules
Mylan (MYL) announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's (PFE) Celebrex Capsules, indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Celecoxib Capsules had U.S. sales of approximately $2.5B for the 12 months ending September 30, 2014.
December 9, 2014
12:22 EDTPFE, BIIBPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information
10:32 EDTPFEPfizer says in talks with FDA on path forward for Mylotarg
Pfizer announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia. Among the highlights are results from several investigator-led, large, randomized studies evaluating the antibody-drug conjugate MYLOTARG in select adult AML populations. Research was presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, December 6-9. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology, said “In particular, we are encouraged by the significant clinical evidence emerging from large randomized trials, such as AML-19 and ALFA-0701, demonstrating a positive impact of MYLOTARG when added to standard first-line treatment for patients with acute myeloid leukemia. We are engaging in discussions with the U.S. FDA and other health authorities to determine the best path forward for MYLOTARG. In addition, we plan to initiate an expanded access protocol for the therapy by the end of 2014 in the United States in patients with relapsed or refractory acute myeloid leukemia for whom there are no other treatment options.”
10:23 EDTLHCGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Eagle (AEO) upgraded to Outperform from Perform at Oppenheimer... Concho Resources (CXO) upgraded to Outperform from Neutral at Macquarie... Hanmi Financial (HAFC) upgraded to Outperform from Market Perform at FBR Capital... LHC Group (LHCG) upgraded to Outperform from Underperform at Credit Suisse... Lincoln Electric (LECO) upgraded to Buy from Neutral at Longbow... Northeast Utilities (NU) upgraded to Outperform from Neutral at Macquarie... SM Energy (SM) upgraded to Outperform from Neutral at Macquarie... Volcano (VOLC) upgraded at Needham... Wells Fargo sees fewer distractions for lululemon (LULU), upgrades shares... Xcel Energy (XEL) upgraded to Outperform from Neutral at Macquarie... lululemon (LULU) upgraded to Outperform from Market Perform at Wells Fargo.
08:50 EDTBBRYBlackBerry CEO says China entry won't be rushed, won't include takeover
BlackBerry (BBRY) Executive Chairman and CEO John Chen, in a post to his LinkedIn account entitled "Don't Believe The Hype," stated that he has recently I’ve been advised to capitalize on Kim Kardashian’s pronouncements that BlackBerry phones are her “heart and soul,” or talk up plans to enter the China market, "however preliminary they are today." Chen said BlackBerry's focus right now is on extending its security foundation with new solutions for the enterprise and that it "cannot and will not" chase sensationalism. "As for China, rest assured that we are developing a well-thought out plan that will take into account many factors, including timing and our long-term strategy. It won’t be rushed because it’s exciting or turned away from because of security concerns. And it won’t include a takeover," Chen wrote in his post. Reference Link
07:44 EDTPFEAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
06:19 EDTLHCGLHC Group upgraded to Outperform from Underperform at Credit Suisse
Credit Suisse upgraded LHC Group two notches to Outperform from Underperform. The firm believes 2015 will be an inflection point for LHC Group given greater visibility on payment cuts, a benign regulatory backdrop, overlooked cost reductions, and an under-levered balance sheet. Price target raised to $32 from $23.
December 8, 2014
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
10:04 EDTACNAccenture and Microsoft launch hybrid cloud platform
Subscribe for More Information
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
05:24 EDTACNAccenture awarded contract by Japan Tourism Agency
The Japan Tourism Agency, or JTA, has awarded Accenture a seven-month contract to provide management consulting services to help increase the number of tourists to Japan. The effort is part of the government’s initiative to attract 20M foreign tourists in the run up to the 2020 Tokyo Olympic and Paralympic Games. Accenture will present recommendations to JTA based on a survey the company develops to better understand the challenges tourists say they face in traveling to the country. The survey, which will be conducted at airports and other travel locations, will examine the environment for welcoming foreign guests in Japan, including communications infrastructure, payment and purchase options and multilingual support options. Results and recommendations will be shared across Japan and abroad.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use